Organophosphorus compounds ascribed to as nerve agents (sarin, soman, tabun, cyclosarin) are highly toxic, and are considered to be the most dangerous chemical compounds. All apparently share a common mechanism of cholinesterase inhibition and can cause similar svmotoms. The . . standard therapy, in the case of organophosphorus poisoning, has the prophylactic use of reversibly acting AChE inhibitors and antidotal administration of AChE reactivators-oximes. Unfortunately, none of these oximes can be regarded as a broad spectrum antidote, ie, effective against all nerve agents. While the presently available oximes (pralidoxime, ohidoxime) are not considered to be sufficiently effective against nerve agents, especially in the case of soman poisoning, the H oximes (HI-6, HLo7) appear to,be very promising antidotes against nerve agents because these are able to protect the experimental animals from toxic effects and improve survival of animals poisoned with supralethal doses. A lot of research has been pursued on the treatment of sarin, soman, and tabun, but cyclosarin was not considered for such a study for a long time. Recently, attention of researchers has also turned to cyclosarin because of its potential use as a chemical warfare agent. Cyclosarin is highly toxic organophosphorus compound which is resistant to conventional oxime therapy. This paper reviews the latest positionof cyclosarin in standpoint of medical treatment by various reactivators considering the ability of various oximes, HI-6, HS-6, BI-6, and KO33 of their reactivation potency.
INTRODUCTION
The organophosphates (OP) are used in agriculture and in veterinary practice. Potential for exposure t o chemical warfare nerve agents such as sarin (GB; 0-isopropylmethylfluorophosphonate), tabun (GA; 0-ethyldimethylamidocyanophosphate), soman (GD; 0-pinacolylmethylfluorophosphonate), VX (0-ethyl-S-(2-diisopropy1aminoethyl)-methyl---thiophosphonate) and cyclosarin (GF; O-cyclohexylmethylfluorophosphonate) [ Structure I] exists on the battlefield (eg, Iran-Iraq war, Desert Storm), or in the civilian sector a s a threat by a terrorist group (eg, Tokyo subway incident), or as an accident as part of current demilitarisation efforts. All apparently share a common mechanism of cholinesterase inhibition and can cause similar symptoms. Because these share this mechanism, exposure t o the same organophosphate by multiple routes or to multiple organophosphates by multiple rou'tes, can lead to serious additive toxicity'.
T h e organophosphates poison insects and mammals primarily by phosphorylation of the acetylcholinesterase enzyme (AChE, E C 3.1.1.7) at nerve endings (Structure 11). T h e result is a loss (salivation, lacrimation, miosis), hypothermia, mild tremors, and mouthasmacking (chewing motions), lowered motor activity, decreased tail-pinch response, and altered neuromuscular function2 (gait changes and increased foot splay). Whereas the neuropathological lesions associated with organophosphates poisoning are well characterised, however, there is considerable lack of information on their behavioural effects, especially after chronic exposure. The importance of neurobehavioural studies lies in the fact that behaviour is considered as a functional end-product of the various sensory, motor, and integrative processes occurring in the nervous system. StructureII: Phosphorylatiouof the acetylculinesteraseenzyme at nerve endings of the available AChE so that the effector organ becomes overstimulated by the excess acetylcholine (ACh) in the nerve ending. The enzyme is critical to normal control of nerve impulse transmission from nerve fibres to smooth and skeletal muscle cells, glandular cells, and autonomic ganglia, as well as within the central nervous system. Some critical proportion of the tissue enzyme mass must be inactivated by phosphorylation before symptoms and signs of poisoning become manifest'.
In animals, generally all cholinesterase inhibitors produce autonomic signs of cholinergic overstimulation This particular aspect, therefore, requires thorough investigation, more so because behavioural changes are now being regarded as a standard indicator of toxicity in human beings and animals, chronically exposed to low concentrations of potential neurotoxicants3. Prolonged epileptic seizures in a nerve agent casualty will produce profound, irreversible, brain damage that, in turn, will result in long-term deficits in cognitive function and behaviour. Combined prophylaxis and therapy regimen, however, does not prevent nerve agent-induced seizures4, although the standard therapy in organophosphates poisoning consists of atropoine along with an AChE reactivators (Structure 111).
Cyclosarin was not considered for such a study for a long time although research on the treatment of sarin, soman, and tabun was p u r s~e d~-~. Recently,
Structure 111: Oximes attention is also turned to cyclosarin* because of its potential use as a nerve agent and its properties are given in Table 1 . The research interest was Table 1 . Properties of cyclosarin 
. IN VZTRO REACTIVATION OF

CYCLOSARIN-INHIBITED AChE
In vitro reactivation of the AChE is commonly used as the screening method for pre-evaluation of the new potential AChE reactivators before the in vivo experiments" 13. Advantage of the in vitro method is the rather quick evaluation of reactivation potency of the AChE reactivators within a short period. The reactivating efficacy of oximes in vitro usually corresponds to their efficacy" in vivo. On the other hand, Lucic15, et al. reported that this rule is not always true. They described samples of the AChE reactivators, which were without biological activity in vitro, however, were potent in vivo.
An important factor, which can influence reactivation of the AChE, is the choice of the suitable animal species. Till today, many species of laboratory animals (mouse, guinea pig, rabbit, rat, and monkey) have been tested as the suitable source of the AChE similar to the human AChE16.17. Another factor, which can influence the results obtained in reactivation process, is the choice of the AChE assay, of which the most common methods are colorimetricz3 and potentiostatic t i t r a t i~n~' -~~. Research works, which focus on the reactivation of cyclosarin inhibited AChE, are not much informative. Some of these are aimed at the preparation or testing of the new AChE re activator^^'-^^, and others aimed at the choice of appropriate specie^^^.'^. A of pralidoxime (2-PAM; 2-hydroxyiminomethyl-llist of the currently tested reactivators of cyclosarinmethylpyridinium chloride) to penetrate the bloodinhibited AChE and conditions of the reactivation brain birrierz1.22.
process are given in Table 2 Pralidoxime Table 2 . List of the currently tested reactivators of cyclosarin-inhibited AChE a n d conditions of the reactivation process 
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The assessment of the reactivating and therapeutic efficacy of oximes in vivo is necessary for estimating the benefits of a new antidote in the treatment of human poisoning with organophosphorus corn pound^^^. The reactivating efficacy is determined by measuring AChE activity in different body parts after intoxication with cyclosarin. The therapeutic efficacy of oximes against supralethal poisoning with cyclosarin is determined by the evaluation of the ED,, values. (100 pmollkg) in brain and diaphragm of rats. The oxime therapy was administered 5 min before intramuscular application of cyclosarin (80 pglkg). BI-6 and methoxime were significantly better reactivators of cyclosarin-inhibited AChE than pralidoxime and obidoxime but not so efficacious as HI-6 and HLo-7. The potency of pralidoxime and obidoxime to reactivate cyclosarin-inhibited AChE in rat diaphragm was very low. In this study, the therapeutic efficacy of the same oximes was determined. The H-oximes including BI-6 are sufficiently effective against supralethal cyclosarin poisoning at doses suggested for human beings (approx. 2 9% of their LD,, values). Pralidoxime is not able to completely protect rats against the supralethal cyclosarin poisoning. Obidoxime is able to protect cyclosarin-poisoned rats but only at a higher dose than that suggested for human beings (3.5 mgtkg). Methoxime is significantly more efficacious than obidoxime and pralidoxime, but its ED,, value is also higher than the dose suggested for human beingsn4 (14 mglkg). After intramuscular administration of cyclosarin in a sublethal dose (54 pglkg), the subsequent (after 30 s) antidotal therapy was more effective when HI-6 (100 p mollkg) was used, because reactivation of AChE in all body parts under study (frontal cortex, pontomedullar region, hypothalamus, hippocampus, basal ganglia and diaphragm) was more marked than in the case of obidoxime (100 p mollkg) as antidotal treatmentz2. When HI-6 was compared with obidoxime in eliminating of stressogenic effect of cyclosarin in rats, it was found that obidoxime had practically no effect, while HI-6 decreased plasma corticosteron level, and liver tyrosine aminotransferase activity increased after cyclosarin poisoning3z. 
Zn Vivo Reactivation in Rats
Therapeutic efficacy of obidoxime and HI-6 in two doses (15 mglkg; 30 mglkg) was studied in mice intramuscularly intoxicated with cyclosarin. HI-6 was found to be better than obidoxime in both doses33. Also pralidoxime (50 mglkg) was compared in therapeutic efficacy with HI-6 (50 mglkg) in mice poisoned s.c. with cyclosarin. Both oximes were applied i.p. in combination with atropine (10 mglkg) and benactyzine (10 mglkg). The protective ratio of HI-6 was seven-fold higher than of pralidoximelZ.
In Vivo Reactivation in Guinea-pigs
Anticonvulsant potency of some anticholinergic and benzodiazepine drugs was tested in guineapigs after intoxication with cyclosarin. Guineapigs were pretreated with pyridostigmine (0.026 mglkg i.m.) 30 min before cyclosarin (2 LD,,; 114 pglkg s.c.), followed 1 min later by pralidoxime (25 mglkg i.m.) and atropine ( 2 mglkg i.m.). Anticholinergics (atropine, trihexyphenidyl, biperiden) or benzodiazepines (diazepam, midazolam) were administered i.m., 5 min after seizure onset. All the drugs were capable of terminating seizure activity, with midazolam and trihexyphenidyl being significantly more potent than the other drugs, and midazolam being more rapid in controlling seizure than atropine, trihexyphenidyl or d i a~e p a m '~. '~.
in Vivo Reactivation in Rhesus Monkeys
The rhesus monkeys were challenged with The therapeutic regimen applied was completely effective against cyclosarin, saving all the 10 animals in each group. The cyclosarin-treated groups had minimal nervous system changes with no significant lesion difference resulting from the different oxime therapies in comparison with non-treated group in which neuronal degenerationlnecrosis and spinal cord hemmorrhage were observed9. When serum and biochemical changes were monitored, it was observed that the early release of serum enzymes which indicated damage to striated or cardiac muscles. There were mild elevations of sodium and potassium levels 2 days after exposure, inferring the presence of hypoxia, metabolic acidosis, slight plasma hyperosmolality, or a combination of these conditions. By 1 week after exposure, the initially elevated levels of creatine kinase, aspartate transaminase, lactate dehydrogenase, and alanine transaminase declined essentially to baseline levels, implying that injury to these tissues was not permanent36.
THERAPEUTIC EFFICACY
A combined regimen of prophylaxis and oxime therapy is now generally considered the most effective medical approach for dealing with the threat of nerve agent poisoning of military personnel3'. Pretreatment with carbamate ChE inhibitors such as pyridostigmine, shields a fraction of ChE in the periphery from irreversible inhibition by the nerve agents. However, pyridostigmine-induced increase in the level of ACh can itself cause symptoms of poisoning. Therefore, it would be useful to counteract the effects of the accumulated ACh using anticholinergic drugs such as benactyzine or trihexyphenidyl. In addition, the combination of pyridostigmine with anticholinergic drugs allows the dose of pyridostigmine that is otherwise limited by symptoms caused by elevated level of ACh to be increased and results in higher prophylactic efficacy than that observed for pyridostigmine alone3*. In the event of poisoning, immediate therapeutic treatment with an anticholinergic drug such as atropine sulphate, antagonizes the effect of excess ACh at muscarinic receptor sites, and an oxime is used to reactivate any unaged inhibited enzyme. The most important oximes are pralidoxime, obidoxime, methoxime, HI-6, and HL67. However, clinical experience has indicated that oximes are not always very efficient reactivators of AChE depending on the type of nerve agent intoxication. Therefore, none of these oximes can be regarded as a broad spectrum antidote, ie, effective against all the nerve agents39. The use of carbamate pretreatment in conjunction with atropine and oxime therapy has been shown to significantly increase the survival rate of experimental animals exposed to multiple LD,, doses of some organophosphate nerve agent^^^.^'.
This combined prophylaxis and oxime therapy regimen, however, does not appear to ameliorate nerve-agent induced, centrally mediated seizure activity and concomitant motor c o n~u l s i o n s~~. Seizure activity in organophosphate intoxication creates a problem for the medical management ofvexposed subjects. Additionally, the seizure activity rapidly progresses to status epilepticu~'~ and contributes to the profound brain damage and cardiac pathology, that develops as a consequence of exposure to these highly toxic compound^^^^^^. Therefore, concomitant administration of an adjunct compound selected for its anticonvulsant activity (eg diazepam) is required to improve the presently utilised regimen of carbamate pretreatment plus atropine and oxime therapy37.
CONCLUSION
The world political scene urges more detailed research on toxic organophosphate compounds and the development of treatment methods of their toxic effects. A comprehensive study on the treatment of cyclosarin toxicity has not been made. Kassa14 reported that there is no single, broad-spectrum oxime suitable for the antidotal treatment of poisoning with all organobhosphate agents1" If more than one oxime is available, the choice depends primary on the identity of the responsible organophosphates. While the presently available oximes (pralidoxime, obidoxime) are not considered to be sufficiently effective against nerve agents1', especially in the case of soman poisoning5, the H oximes (HI-6, HLo7) appear to be very promising antidotes against nerve agents because they are able to protect experimental animals from toxic effects and improve survival of animals poisoned with supralethal doses". As a result, the effects of these reactivators in counteracting cyclosarin toxicity have to be examined. According to the latest in vitro studies, oximes HI-6, HS-6, BI-6, and KO33 seem to be promising because of their reactivation potency27. 29 
